Geron (GERN) Stock News

Geron Corporation (Nasdaq: GERN) reported strong Q2 2025 financial results, highlighting $49.0 million in RYTELO® net product revenue, representing a 24% increase from Q1. The company announced the appointment of Harout Semerjian as President and CEO and reported significant commercial progress with over 1,000 ordering accounts.

Key financial metrics include a reduced net loss of $16.4 million ($0.02 per share), compared to $67.4 million in Q2 2024. The company maintains a strong cash position of $432.6 million. The Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis has reached 95% enrollment, with full enrollment expected by year-end 2025.

Geron Corporation (Nasdaq: GERN) has appointed Harout Semerjian as its new President and Chief Executive Officer, effective immediately. Semerjian brings over 30 years of commercial experience in hematology and oncology, including significant leadership roles at Novartis, Ipsen, and GlycoMimetics. He succeeds Dawn Carter Bir, who served as Interim President and CEO since March 2025 and will remain on Geron's Board of Directors.

The appointment comes at a crucial time as Geron focuses on expanding the reach of its product RYTELO and advancing its late-stage pipeline, including the IMpactMF Phase 3 trial in relapsed/refractory myelofibrosis. Semerjian's extensive experience includes leading global commercial operations for key hematology therapies like Gleevec® and KISQALI®.

Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, has scheduled its second quarter 2025 financial results announcement for August 6, 2025, before market open. The company will host a conference call at 8:00 a.m. Eastern Time to discuss financial results and business highlights.

The announcement will be available through a press release on the company's website, along with a live webcast of the conference call and presentation. The webcast recording will remain accessible on Geron's website for 30 days following the event.

Geron Corporation (Nasdaq: GERN) has granted equity inducement awards to five newly hired employees. The awards, granted on July 17, 2025, include 228,000 stock options with an exercise price of $1.29 per share and 114,000 restricted stock units (RSUs).

The stock options have a ten-year term with a 4-year vesting schedule, starting with 12.5% vesting after six months and the remainder vesting over 42 months. The RSUs vest 25% annually over four years. These awards were granted under Geron's 2018 Inducement Award Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

Geron Corporation (GERN) has granted equity awards totaling 1,116,000 shares to 16 new employees as employment inducement. The grants include 744,000 stock options priced at $1.45 per share with a 10-year term, vesting over 4 years with 12.5% vesting at 6 months and the remainder over 42 months. Additionally, 372,000 RSUs were awarded, vesting 25% annually over 4 years. The awards were granted on June 17, 2025, by Geron's Compensation Committee under Nasdaq Rule 5635(c)(4) and are subject to the company's 2018 Inducement Award Plan terms.

Geron Corporation (GERN) announced new presentations at ASCO and EHA 2025 highlighting RYTELO® (imetelstat) efficacy and safety data. New post-hoc analyses from the IMerge trial demonstrate clinical benefits in lower-risk myelodysplastic syndromes (LR-MDS) patients, regardless of ring sideroblast status, baseline serum erythropoietin levels, or prior therapy use. The data shows RYTELO's effectiveness in achieving transfusion independence across various patient subgroups. Updates on the IMpactMF trial revealed ~80% enrollment completion as of February 2025. The IMproveMF trial, studying imetelstat combined with ruxolitinib, showed promising preliminary results with good tolerability and encouraging dose-dependent efficacy data. Patient-centric outcomes demonstrated sustained quality-of-life improvements and longer duration without transfusion reliance compared to placebo.

Geron Corporation (GERN) has granted equity awards totaling 411,000 shares to six new employees as employment inducement. The awards, granted on May 16, 2025, consist of:

- Stock options to purchase 274,000 shares at $1.27 per share (closing price on grant date), with a 10-year term and 4-year vesting schedule

- Restricted Stock Units (RSUs) representing 137,000 shares, vesting 25% annually over 4 years

The grants were approved by Geron's Compensation Committee under Nasdaq Rule 5635(c)(4) and are subject to the company's 2018 Inducement Award Plan terms.

Geron Corporation (GERN) reported Q1 2025 financial results, with RYTELO® net product revenue of $39.4M, down from $47.5M in Q4 2024 due to inventory drawdown. The company posted a net loss of $19.8M ($0.03 per share), improved from $55.4M loss in Q1 2024. Key highlights include: European Commission marketing authorization for RYTELO for lower-risk MDS treatment, with EU launch planned for 2026; approximately 85% enrollment in Phase 3 IMpactMF trial for myelofibrosis, with interim analysis expected in 2H 2026. Cash position stands at $457.5M as of March 31, 2025. Operating expenses were $56.3M, with the company maintaining its 2025 guidance of $270-285M in total operating expenses.

Geron (Nasdaq: GERN) has granted equity awards totaling 1,551,000 shares to twelve new employees as employment inducement. The grants, issued on April 17, 2025, include:

• 1,034,000 shares as stock options with $1.27 per share exercise price
• 517,000 shares as restricted stock units (RSUs)

The stock options have a 10-year term with a vesting schedule of 12.5% after six months and the remaining over 42 months. RSUs vest 25% annually over four years. These awards were approved by Geron's Compensation Committee under Nasdaq Rule 5635(c)(4) and are subject to the company's 2018 Inducement Award Plan.